Alveolar Rhabdomyosarcoma: Understanding Your Pathology Report

Section Editor: Bibianna Purgina MD FRCPC
September 19, 2026


Print this article

Alveolar rhabdomyosarcoma is a type of cancer that develops from cells that would normally become skeletal muscle. Skeletal muscle is the muscle that moves the arms, legs, and other parts of the body. It is a type of sarcoma, a cancer that begins in the body’s connective tissues. It is one of four main types of rhabdomyosarcoma, along with embryonal, spindle cell/sclerosing, and pleomorphic rhabdomyosarcoma.

The name comes from how the tumor looks under the microscope. The cells sit in nests separated by thin bands of tissue, and the cells in the center of each nest often pull apart from one another. This creates spaces that resemble the air sacs, or alveoli, of the lung. The tumor does not start in the lung.

Alveolar rhabdomyosarcoma most often develops in the arms and legs, the trunk, and the area around the anus and genitals. It can also start in the head and neck. It grows quickly and more often spreads to the lymph nodes, lungs, and bone than other types of rhabdomyosarcoma.

This article explains how doctors diagnose alveolar rhabdomyosarcoma and what the fusion result, margins, lymph nodes, and stage in your pathology report mean.

What causes alveolar rhabdomyosarcoma?

Most alveolar rhabdomyosarcomas are caused by a fusion, which is an abnormal joining of two genes that are normally separate. In this tumor, a gene called FOXO1 joins with either PAX3 or PAX7. The result is written as PAX3::FOXO1 or PAX7::FOXO1.

The fusion gene makes an abnormal protein that turns on growth signals and blocks the normal signals that tell a cell to stop dividing or to die. The tumor cells then multiply without the usual controls.

A small group of tumors that look alveolar under the microscope have no FOXO1 fusion. These are called fusion-negative, and they behave more like embryonal rhabdomyosarcoma. The fusion develops in the tumor cells during a person’s lifetime. It is not inherited and cannot be passed on to children.

What are the symptoms of alveolar rhabdomyosarcoma?

The symptoms of alveolar rhabdomyosarcoma depend on where the tumor starts and how large it is. Because the tumor grows quickly, symptoms often develop over weeks to months:

  • Arms or legs. A growing lump, swelling, pain, or difficulty moving the affected limb.
  • Head and neck. Facial swelling, a blocked nose, nosebleeds, fullness in the ear, or vision changes.
  • Near the spine. Numbness, weakness, pain in the legs, or difficulty walking.
  • Pelvis, genitals, or the area around the anus. Trouble passing urine or stool, pelvic pain, or a lump in the groin.

How is the diagnosis made?

The diagnosis of alveolar rhabdomyosarcoma is made after a pathologist examines a sample of the tumor under the microscope. The sample is usually obtained by a biopsy, using a needle or a small incision. In some cases, the surgeon removes the whole tumor during the first operation.

Under the microscope, alveolar rhabdomyosarcoma is made of small, round cells with dark nuclei. Pathologists describe this appearance as a small round blue cell tumor. The cells are arranged in nests separated by thin bands of fibrous tissue, and many of the cells are dividing. Other cancers can look very similar, including Ewing sarcoma, neuroblastoma, and lymphoma, so additional tests are always needed.

Molecular testing looks for the FOXO1 fusion. Two tests are commonly used. FISH uses glowing probes to show that the FOXO1 gene has broken apart. Next-generation sequencing (NGS) reads the genetic material and names the partner gene, PAX3 or PAX7. Your report will state which test was used and what was found.

Once alveolar rhabdomyosarcoma is confirmed, imaging tests show how far the tumor has spread. These usually include MRI or CT of the tumor site and a CT scan of the chest. Because this tumor can reach the bone marrow, doctors may also examine a bone marrow sample. The next section describes the immunohistochemistry tests used to confirm the diagnosis.

Immunohistochemistry

Immunohistochemistry uses antibodies to show which proteins tumor cells make. For alveolar rhabdomyosarcoma, it confirms that the tumor cells are developing skeletal muscle cells. It also separates this tumor from other small round blue cell tumors. Your report may include some of the following:

  • Desmin. This muscle protein is positive in alveolar rhabdomyosarcoma.
  • Myogenin. This protein is found only in developing skeletal muscle cells. In alveolar rhabdomyosarcoma, it is usually positive in nearly all of the tumor cells. In embryonal rhabdomyosarcoma, the staining is typically patchy.
  • MyoD1. This protein is also found in developing skeletal muscle. It is usually positive, and the staining must be nuclear to count as a positive result.

These stains confirm that the tumor is a rhabdomyosarcoma. They do not tell the pathologist whether a FOXO1 fusion is present, so molecular testing is also needed.

Histologic grade

Pathologists do not assign an FNCLCC grade to alveolar rhabdomyosarcoma. All types of rhabdomyosarcoma are treated as high-grade cancers, so your report will usually not include a grade. A report without a grade is not incomplete.

For this tumor, the fusion result gives far more information about expected behavior than a grade would.

Tumor size

Tumor size is the greatest dimension of the alveolar rhabdomyosarcoma, measured in centimeters (cm). The size may come from imaging or from the tumor removed at surgery. Tumors 5 cm or smaller are associated with a more favorable outcome, and size is used to assign stage.

Tumor extension

Tumor extension describes whether alveolar rhabdomyosarcoma has grown into nearby structures such as muscle, bone, nerves, blood vessels, or organs. When the tumor is removed, the pathologist examines the surrounding tissue and reports which structures contain tumor cells. A tumor that has grown into nearby structures is described as invasive, and this affects both the stage and the plan for surgery and radiation.

Treatment effect

Most people with alveolar rhabdomyosarcoma receive chemotherapy, and often radiation therapy, before surgery. When the tumor is removed after this treatment, the pathologist examines it to see whether living tumor cells remain.

For rhabdomyosarcoma, no specific percentage of dead tumor is used to guide treatment. Your team judges the response to treatment mainly with imaging and interprets the pathology findings alongside those results.

Lymphovascular invasion

Lymphovascular invasion means that cells from the alveolar rhabdomyosarcoma are seen inside a small blood vessel or lymphatic channel. These vessels give cancer cells a route to lymph nodes and other parts of the body.

  • Present. Tumor cells were seen inside a vessel. This finding is associated with a higher risk of tumor spread.
  • Not identified. No tumor cells were seen inside vessels in the tissue examined.

Perineural invasion

Perineural invasion means tumor cells are growing around or along a nerve. A pathologist may mention it when it is seen in alveolar rhabdomyosarcoma. When present, it suggests the tumor may extend beyond its visible edge and may raise the risk of the tumor coming back in the same place.

Surgical margins

Margins are the edges of tissue cut by the surgeon to remove an alveolar rhabdomyosarcoma. The pathologist inks these edges and examines them under the microscope.

  • Negative margin. No tumor cells are seen at the inked edge. The report may also give the distance between the tumor and the closest margin.
  • Positive margin. Tumor cells reach the inked edge, and some tumor may remain. Further surgery or radiation therapy may be considered.

Margins are only reported when the tumor was removed rather than sampled. For many rhabdomyosarcomas, complete removal at the first operation is not possible without harming an important structure. In those situations, a biopsy alone is the correct first step, and chemotherapy and radiation are used to control the tumor.

Lymph nodes

Lymph nodes are small immune organs found throughout the body. Alveolar rhabdomyosarcoma reaches the nodes near where it started more often than most other sarcomas. For this reason, doctors often check nodes as part of staging, even when imaging looks normal.

A sentinel lymph node biopsy, which removes only the first node or nodes the tumor would reach, is sometimes used. When doctors remove nodes, the report lists how many were examined and how many contain tumor cells. Tumor found in a lymph node raises both the stage and the risk group, and it is associated with a less favorable outcome.

Biomarker and molecular testing

For alveolar rhabdomyosarcoma, the molecular result does more than confirm the diagnosis. The fusion result is used to assign the risk group and predicts how the tumor is likely to behave. Your report may describe one of the following results:

  • PAX3::FOXO1 fusion. This is the most common result, found in roughly 6 in 10 alveolar rhabdomyosarcomas. In cooperative group studies, this fusion was the strongest molecular predictor of a less favorable outcome, for both tumors that had spread and those that had not.
  • PAX7::FOXO1 fusion. This fusion is less common, found in roughly 1 in 5 tumors. It tends to occur in younger children and is associated with a more favorable outcome than PAX3::FOXO1.
  • FOXO1 break without a named partner. FISH can show that FOXO1 has broken apart without identifying the partner gene. When this matters for treatment, a second test may be done to name the partner.
  • No FOXO1 fusion (fusion-negative). About 1 in 10 tumors that look alveolar have no fusion. These behave more like embryonal rhabdomyosarcoma, and treatment follows the plan used for fusion-negative disease.

No drug is currently approved to target these fusions. The results are used for risk grouping and to find clinical trials. You can learn more about tumor testing in our Biomarkers and Genetic Testing section.

Stage, clinical group, and risk group

Rhabdomyosarcoma in children, including alveolar rhabdomyosarcoma, is described by three separate systems. All three may appear in the medical record.

  • Stage, from 1 to 4. This is based on where the tumor started, its size, whether lymph nodes are involved, and whether it has spread to distant sites. Sites are divided into favorable and unfavorable. Favorable sites include the area around the eye, the head and neck away from the lining of the brain, and the biliary tract. They also include the urinary and reproductive organs, except the bladder and prostate.
  • Clinical group, from I to IV. This is based on how much tumor was removed at the first operation. Group I means the tumor was completely removed. Group II means small amounts remained or a lymph node was involved. Group III means visible tumor remained, which includes tumors that were only biopsied. Group IV means the tumor had already spread to distant sites.
  • Risk group: low, intermediate, or high. This combines stage, clinical group, FOXO1 fusion status, and age and site. The risk group determines treatment intensity.

The pathology report provides several of these ingredients but usually does not state the risk group itself. The treating team assigns it once the imaging, surgery, and molecular results are available.

In adults, the pathology report may instead include a pathologic stage (pTNM) from the American Joint Committee on Cancer (AJCC), 8th edition. For tumors of the arms, legs, and trunk, the tumor stage (pT) is based on size. Other body sites use different rules.

  • pT1. The tumor is 5 cm or smaller.
  • pT2. The tumor is larger than 5 cm but not larger than 10 cm.
  • pT3. The tumor is larger than 10 cm but not larger than 15 cm.
  • pT4. The tumor is larger than 15 cm.

The nodal stage for adults is pN0 if no tumor cells were found in the lymph nodes examined and pN1 if tumor cells were found. If no lymph nodes were removed, the report will usually say that pN was not assigned.

What is the prognosis?

The outlook for a person with alveolar rhabdomyosarcoma depends mainly on whether the cancer has spread and on which fusion is present. In a large cooperative group analysis, about 65% of people whose cancer had not spread were alive five years after diagnosis. For people whose cancer had already spread, that figure was about 22%.

These numbers describe groups of people and cannot predict what will happen in one person. Treatment continues to change, and children generally do better than adults with the same diagnosis.

Features associated with the outcome of alveolar rhabdomyosarcoma include:

  • Spread at diagnosis. This is the strongest predictor of a less favorable outcome, especially when the cancer has reached bone or bone marrow.
  • Fusion result. PAX3::FOXO1 is associated with a less favorable outcome than PAX7::FOXO1 or fusion-negative disease.
  • Lymph node involvement. Tumor in nearby nodes is associated with a less favorable outcome.
  • Tumor remaining after surgery. A higher clinical group is associated with a less favorable outcome.
  • Tumor size and invasion. Tumors larger than 5 cm, and tumors that have grown into nearby structures, do less well.
  • Age. Children between 1 and 9 years old tend to do better than adolescents and adults.

What happens after the diagnosis?

After a team confirms alveolar rhabdomyosarcoma, it usually plans care with an oncologist, surgeon, radiation oncologist, and pathologist. The findings in the pathology report, especially the fusion result, the margins, and the lymph nodes, are combined with imaging to assign the risk group and plan treatment.

  • Chemotherapy. Everyone with alveolar rhabdomyosarcoma receives chemotherapy because tumor cells may be present elsewhere in the body without being visible on scans. A common combination is vincristine, actinomycin D, and cyclophosphamide, with additional drugs for higher-risk disease.
  • Surgery and radiation therapy. The original tumor is controlled with surgery, radiation, or both. Radiation is used in most people with this type, including when chemotherapy has worked well.
  • Lymph node surgery. Doctors may sample or remove nodes to stage the disease accurately, especially for tumors of the arms, legs, and trunk.
  • Clinical trials. Children are usually treated on a protocol developed by a cooperative research group, and providers should discuss trials for high-risk disease.

After treatment ends, follow-up with regular imaging continues for several years, because the cancer can come back. For children, long-term follow-up also monitors chemotherapy and radiation effects on growth, fertility, and organ function.

Questions to ask your doctor

  • Which fusion was found: PAX3::FOXO1, PAX7::FOXO1, or no fusion?
  • Which test was used to look for the fusion?
  • Is the primary site considered favorable or unfavorable?
  • What stage and clinical group have been assigned, and what do they mean?
  • Which risk group does this fall into?
  • Has the cancer spread to lymph nodes, lungs, bone, or bone marrow?
  • Was the whole tumor removed, and were the margins negative?
  • Will lymph nodes be sampled or removed?
  • Which chemotherapy regimen is recommended, and for how long?
  • Will radiation therapy be part of the plan, and which area will be treated?
  • Is there a clinical trial available for this diagnosis?
  • What follow-up will be needed after treatment, and for how long?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?